Other

The Penn State Research Foundation

Research, Incorporated

The Penn State University Research Foundation

Scully, Scott, Murphy & Presser, P.c.

Mclaughlin, Patricia J.

Zagon, Ian S.

Sassani, Joseph W.

Ian S Zagon

Patricia J McLaughlin

Jill P Smith

Michael F Verderame

Joseph W Sassani

Moshe Rogosnitzky

Patricia J Mclaughlin

The present invention relates to pharmaceutical compositions for treating neoplasias in an animal or human comprised of a carrier and therapeutically effective amounts of at least one chemotherapeutic agent along with the biotherapeutic endogenous pentapeptide Met-enkephalin, referred to as opioid growth factor. Also provided are methods of treating neoplasias in an animal or human in need of such treatment, comprising the administration to the animal or human therapeutically effective amounts of a pharmaceutical composition comprised of a carrier and therapeutically effective amounts of at least one neoplasia-treating agent, such as a chemotherapeutic agent or radiation, along with opioid growth factor.

Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor

The invention relates to treatment of epithelial wounds. In particular, the invention relates to methods and formulations for treating epithelial wounds based on application of an opioid antagonist such as naltrexone.

Methods and compositions for treatment of epithelial wounds

This invention relates to treatment of epithelial wounds. In particular, the invention relates to methods and formulations for treating epithelial wounds based on application of an opioid antagonist such as naltrexone.

This invention relates to treatment of dry eye. In particular, the invention relates to methods and formulations for treating dry eye based on topical application of opioid antagonists such as naltrexone.

Methods and compositions for treating dry eye

Methods for the treatment of inflammatory and ulcerative diseases of the bowel (e.g., Crohn's disease and ulcerative colitis) with a therapeutically effective dose less than 50 mg. of opioid antagonists (e.g., naltrexone, nalmefene or naloxone) are disclosed. An embodiment of the invention includes a method of pharmaceutical treatment comprising orally administering to a human subject having Crohn's disease or ulcerative colitis a therapeutic pharmaceutical composition once per day in the evening or at bedtime, wherein the pharmaceutical composition comprises form about 3 mg to about 4.5 mg of naltrexone, nalmefene, naloxone, or a hydrochloride salt thereof in an immediate release solid dosage formulation.

Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists

The present invention provides methods of cell cycle control by administering opioid growth factor (OGF), which activates opioid growth factor receptor (OGFr) signaling. Particularly, the present invention provides a method for monitoring OGF modulation or treatment of a cell proliferation or growth related condition in a subject by assessing the level of the cyclin dependent kinase inhibitor (CKI) relevant or corresponding to the condition. The present invention also provides a method for screening the eligibility of a subject for OGF modulation or treatment by assessing the level of OGF receptor (OGFr) and the relevant CKI. A method for enhancing the efficacy of OGF therapy by increasing the level of the relevant CKI and/or OGFr is also provided.

Cyclin-dependent kinase inhibitors as targets for opiod growth factor treatment

This invention relates to novel nucleic acid molecules coding for opioid growth factor receptors. In particular, the present invention provides isolated nucleic acid molecules coding for human and rat OGF receptors. Antisense molecules, expression vectors and host cells, isolated proteins encoded by such nucleic acid molecules, antibodies directed against such proteins, as well as pharmaceutical compositions derived therefrom are also included. The invention further provides methods of modulating cell growth by using the isolated nucleic acid molecules, the antisense molecules and the antibodies directed against the encoded proteins.

Opioid growth factor receptors

Methods of detecting opioid growth factor receptor (OGFr) in tissue

Nucleic acid molecules encoding opioid growth factor receptors

The present invention is related to the treatment and prevention of cancer including particularly gastrointestinal cancer. More specifically, the present invention describes the use of naltrexone, naloxone and the pentapeptide growth factor &lsqb;Met &rsqb;-enkephalin to inhibit and arrest the growth of cancer. Such efficiency has been discovered to be a consequence of the functional manipulation of the zeta (&zgr;) opioid receptor through endogenous &lsqb;Met &rsqb;-enkephalin. This receptor has been determined to be present in growing cancers such as pancreatic and colon cancer, for example.

Control of cancer growth through the interaction of &lsqb;MET5&rsqb;-enkephalin and the zeta receptor

The present invention is related to the treatment and prevention of cancer including particularly gastrointestinal cancer. More specifically, the present invention describes the use of naltrexone, naloxone and the pentapeptide growth factor [Met.sup.5 ]-enkephalin to inhibit and arrest the growth of cancer. Such efficiency has been discovered to be a consequence of the functional manipulation of the zeta (.zeta.) opioid receptor through endogenous [Met.sup.5 ]-enkephalin. This receptor has been determined to be present in growing cancers such as pancreatic and colon cancer, for example.

Control of cancer growth through the interaction of [Met.sup.5

A method for regulating the growth processes in a myriad of cells, tissues, organ systems and unicellular and multicellular organisms including plants, animals and man by the administration of effective amounts of the opioid antagonists naloxone, naltrexone, their analogs, metabolites derivatives, and/or mixtures thereof. At the cellular level, the growth processes entail all mitetic events and related processes including cell proliferation, as well as cell migration and cell differentiation, and at the somatic or organismal level, anatomical, behavioral and neurological development, metamorphisis and maturation. Growth regulation can be effected in vivo and/or in vitro.

Growth regulation and related applications of opioid antagonists

A method for regulating the growth processes in a myriad of cells, tissues, organ systems and unicellular and multicellular organisms including plants, animals and man by the administration of effective amounts of the opioid antagonists naloxone, naltrexone, their analogs, metabolites derivatives, and/or mixtures thereof. At the cellular level, the growth processes entail all mitotic events and related processes including cell proliferation, as well as cell migration and cell differentiation, and at the somatic or organismal level, anatomical, behavioral and neurological development, metamorphisis and maturation. Growth regulation can be effected in vivo and/or in vitro.

Growing community of inventors

Hummelstown, PA, United States of America

Ian S Zagon